Novo Nordisk's Calculus: Smaller Doses, Microbiome Bets, and a Share Price in the Weeds

Novo Nordisk recalibrates obesity strategy with lower-dose oral semaglutide, microbiome supplements, and AI partnerships, while defending patents and managing manufacturing setbacks.

The Danish pharmaceutical heavyweight has spent the summer quietly repositioning itself for a market that its own chief executive believes investors are misreading. While the stock trades roughly a quarter below its January peak, the company's research engine is firing on multiple fronts — from oral semaglutide pills at lower strengths to microbiome-based supplements that could one day complement its blockbuster GLP-1 franchise.

A Strategy of Calibration, Not Escalation

On August 12, Novo Nordisk launched the late-stage OASIS-5 trial, a study designed to pinpoint the lowest effective maintenance dose of its Wegovy pill for weight management. The investigation, which Reuters reported will run through 2028, runs parallel to a separate Phase 3 study involving 450 participants across 62 sites in the US and Europe, also examining reduced doses of oral semaglutide. The message is deliberate: rather than chasing maximum potency, the company wants to offer the most appropriate dose for each patient profile.

That philosophy found a voice the following day, when CEO Mike Doustdar told Reuters that the obesity market will not be a winner-take-all contest against Eli Lilly. Doustdar argued that demand for differentiated treatments — particularly oral formulations — is being underestimated by investors. It's a framing that explains the company's early-August announcement of the Wegovy pill in Germany, a market where oral alternatives to injections have been scarce.

Beyond the Molecule: Microbiome and Machine Learning

The dosing strategy is only one strand of a broader diversification effort. A separate collaboration with Novonesis is examining whether microbiome-based nutritional supplements can amplify the effects of GLP-1 medications like Wegovy. Reuters reports that results from this joint investigation are not expected until the second half of 2027 — a timeline that underscores how far the company is willing to look beyond its current product cycle.

That long horizon extends to the company's digital infrastructure as well. Early August brought news of a strategic partnership with AWS aimed at accelerating drug discovery through artificial intelligence, including the establishment of a hub in London. Doustdar has also indicated the company is evaluating acquisition targets while simultaneously stepping up its research tempo.

Legal Wins and Manufacturing Headaches

Not all recent developments have been forward-looking. In the Netherlands, Novo Nordisk secured a preliminary injunction in early August regarding a patent dispute over Ceban, an unauthorized imitation semaglutide nasal spray. The ruling is a concrete victory for brand protection, underscoring the company's determination to control its molecular family.

On the flip side, Scholar Rock withdrew its European marketing application for a spinal muscular atrophy treatment after problems emerged at a manufacturing facility owned by Novo Nordisk. Scholar Rock said it would resubmit using a different production site. While not a setback for Novo Nordisk's own portfolio, the episode highlights the complications that arise when a pharmaceutical company provides contract manufacturing for third parties.

The Buyback Machine Keeps Running

Capital returns have continued alongside the research push. The company resumed its share repurchase program on August 24, a program that began in May. The buyback activity has been steady: 200,000 B-shares at an average of 303.97 Danish kroner on August 10, another 200,000 at 297.68 kroner on August 13, and a further 200,000 at 299.04 kroner the following day.

The consistent repurchases signal management's conviction that the current valuation is attractive, even as research expenditures mount.

A Stock Caught Between Vision and Valuation

The market's response to all this activity has been muted at best. The shares closed at 40.20 euros, up 0.5 percent on the day and 1.7 percent on the week, but the longer-term picture remains strained. Over the past 30 days, the stock has fallen 8.1 percent, and it now sits 8.7 percent below its level at the start of the year. The gap from the 52-week high of 54.86 euros, reached in January, has widened to roughly 27 percent, though the stock remains well above its March low of 30.25 euros.

The most recent seven trading sessions offered a modest reprieve, with a 3.3 percent gain following a 6.7 percent decline in the preceding 30 days. At 40.81 euros, the shares reflect a market that is neither fully embracing the pipeline narrative nor abandoning the company's long-term prospects.

The pivotal studies — from the low-dose pill trials to the microbiome collaboration — will not produce definitive data for years. Until then, Novo Nordisk's strategy rests on a bet that patience will be rewarded, and that the market's current skepticism represents a mispricing of optionality rather than a correct assessment of competitive risk.